Literature DB >> 3531023

Activity of the trometamol salt of fosfomycin in an in vitro model of the treatment of bacterial cystitis.

D Greenwood.   

Abstract

The response to trometamol fosfomycin of four strains of Escherichia coli was studied in an in vitro model in which the hydrokinetic aspects of the treatment of bacterial cystitis can be stimulated. Two strains of E. coli that were fully susceptible to fosfomycin, and a strain of intermediate susceptibility responded well to relatively low concentrations of the trometamol salt: doses achieving peak concentrations of 50 or 250 mg/l suppressed bacterial growth for at least 18 h; however, the emergence of resistance was completely suppressed only when a peak concentration of 2500 mg/l was achieved in the bladder model. A strain of E. coli that was fully resistant to fosfomycin in conventional minimum inhibitory concentration titrations responded to the highest dosage used, but this did not prevent further resistance from emerging. These results were obtained in the absence of the potentiating agent, glucose-6-phosphate, which is commonly used in susceptibility tests of fosfomycin. The implications of the results for fosfomycin dosage in bacterial cystitis and for the interpretation of susceptibility tests is discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3531023     DOI: 10.1007/bf01645261

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  Factors influencing the response of Escherichia coli to antibiotics in conditions prevailing in the infected urinary bladder.

Authors:  D Greenwood; F O'Grady
Journal:  Br J Exp Pathol       Date:  1976-06

2.  Factors influencing the activity of the trometamol salt of fosfomycin.

Authors:  D Greenwood; A Jones; A Eley
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

Review 3.  An in vitro model of the urinary bladder.

Authors:  D Greenwood; F O'Grady
Journal:  J Antimicrob Chemother       Date:  1978-03       Impact factor: 5.790

4.  Estimation of residual urine volume with 131 I-hippuran.

Authors:  D G Shand; J C MacKenzie; W R Cattell; J Cato
Journal:  Br J Urol       Date:  1968-04

5.  An in-vitro model simulating the hydrokinetic aspects of the treatment of bacterial cystitis.

Authors:  D Greenwood
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

6.  International collaborative study on standardization of bacterial sensitivity to fosfomycin.

Authors:  J M Andrews; F Baquero; J M Beltran; E Canton; F Crokaert; M Gobernado; R Gomez-Ius; E Loza; M Navarro; T Olay
Journal:  J Antimicrob Chemother       Date:  1983-10       Impact factor: 5.790

7.  Factors affecting antibiotic concentrations in bladder urine.

Authors:  Y Kawada; D Greenwood; F O'Grady
Journal:  Invest Urol       Date:  1980-05

8.  In vitro veritas? Antimicrobial susceptibility tests and their clinical relevance.

Authors:  D Greenwood
Journal:  J Infect Dis       Date:  1981-10       Impact factor: 5.226

9.  Pharmacokinetics of fosfomycin.

Authors:  W M Kirby
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

10.  The mechanism of action of fosfomycin (phosphonomycin).

Authors:  F M Kahan; J S Kahan; P J Cassidy; H Kropp
Journal:  Ann N Y Acad Sci       Date:  1974-05-10       Impact factor: 5.691

  10 in total
  4 in total

1.  Activity of fosmidomycin in an in vitro model of the treatment of bacterial cystitis.

Authors:  Y Kanimoto; D Greenwood
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

Review 2.  Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.

Authors:  S S Patel; J A Balfour; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 3.  Review of published studies on single dose therapy of urinary tract infections.

Authors:  R R Bailey
Journal:  Infection       Date:  1990       Impact factor: 3.553

4.  Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.

Authors:  Zackery P Bulman; Miao Zhao; Michael J Satlin; Liang Chen; Barry N Kreiswirth; Thomas J Walsh; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  Int J Antimicrob Agents       Date:  2018-02-24       Impact factor: 5.283

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.